These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 619945)

  • 1. Contribution of individual differences in gastric emptying to variability in plasma propranolol concentrations.
    Castleden CM; George CF; Short MD
    Br J Clin Pharmacol; 1978 Feb; 5(2):121-2. PubMed ID: 619945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil.
    Hughes GS; Heald DL; Patel R; Spillers CR; Batts DH; Euler AR
    Methods Find Exp Clin Pharmacol; 1990 Apr; 12(3):197-204. PubMed ID: 2352449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man.
    Cid E; Mella F; Lucchini L; Cárcamo M; Monasterio J
    Biopharm Drug Dispos; 1986; 7(6):559-66. PubMed ID: 3828485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticholinergics and gastric emptying.
    Hurwitz A; Robinson RG; Herrin WF; Christie J
    Clin Pharmacol Ther; 1982 Feb; 31(2):168-74. PubMed ID: 6895722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration effect studies with oral metoclopramide.
    Bateman DN; Kahn C; Davies DS
    Br J Clin Pharmacol; 1979 Aug; 8(2):179-82. PubMed ID: 486293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.
    Liddle RA; Rushakoff RJ; Morita ET; Beccaria L; Carter JD; Goldfine ID
    J Clin Invest; 1988 Jun; 81(6):1675-81. PubMed ID: 3290250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
    Wells PG; Feely J; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1983 May; 33(5):603-8. PubMed ID: 6839632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma propranolol concentration and dose in young, healthy volunteers.
    Dey M; Brisson J; Davis G; Enever R; Pray K; Zaim B; Dvornik D
    Biopharm Drug Dispos; 1986; 7(2):103-11. PubMed ID: 3708118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man.
    Von Bahr C; Hermansson J; Tawara K
    Br J Clin Pharmacol; 1982 Jul; 14(1):79-82. PubMed ID: 7104170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To determine the effect of metoclopramide on gastric emptying in severe head injuries: a prospective, randomized, controlled clinical trial.
    Marino LV; Kiratu EM; French S; Nathoo N
    Br J Neurosurg; 2003 Feb; 17(1):24-8. PubMed ID: 12779198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of age on plasma levels of propranolol and practolol in man.
    Castleden CM; Kaye CM; Parsons RL
    Br J Clin Pharmacol; 1975 Aug; 2(4):303-6. PubMed ID: 1233989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent disposition of oral propranolol in normal subjects.
    Mackichan JJ; Pyszczynski DR; Jusko WJ
    Biopharm Drug Dispos; 1980; 1(4):159-66. PubMed ID: 7448344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects.
    Walle T; Walle UK; Cowart TD; Conradi EC
    Clin Pharmacol Ther; 1989 Sep; 46(3):257-63. PubMed ID: 2776391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.